Laurie Barclay, MD
NEW YORK (MedscapeWire) Apr 15 Fluoxetine is safe and effective in body dysmorphic disorder (BDD) with or without delusions, according to results of a randomized, placebo-controlled trial in the April issue of the Archives of General Psychiatry.
"Available data suggest that this disorder may respond to serotonin reuptake inhibitors," write Katharine A. Phillips and colleagues from Butler Hospital in Providence, Rhode Island. "However, no placebo-controlled treatment studies of BDD have been published."
In this parallel-group study, 67 patients meeting DSM-IV criteria for BDD with or without delusions received 1 week of single-blind placebo treatment followed by 12 weeks of double-blind treatment with fluoxetine or placebo.
On the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder, fluoxetine was significantly more effective than placebo for BDD beginning at week 8 and continuing at weeks 10 and 12 (P < .001). The response rate was 53% for fluoxetine and 18% for placebo (P=.003).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!